ViroPharma's HCV-796 phase 1a study supports more trials

By Jennifer Chiou

New York, May 1 - ViroPharma Inc. announced that pharmacokinetic data from a phase 1a trial of HCV-796 for hepatitis C showed that the safety and profile of the compound justified additional clinical evaluations.

HCV-796 is an orally dosed non-nucleoside viral polymerase inhibitor with potential to interfere with the replication of the hepatitis C virus. The company is co-developing the drug with Wyeth Pharmaceuticals.

"Overall, the findings demonstrate that the absorption and elimination profile, distribution, half life, and tolerability of HCV-796 are acceptable, and supportive of our ongoing clinical development," ViroPharma vice president of clinical research and development said in a news release.

The study was an ascending single dose, placebo-controlled trial in which fasting healthy subjects were randomly assigned to receive 25, 50, 100, 250, 500, 1000 or 2000 mg oral doses of HCV-796.

Overall, the company said the safety profile showed that single oral doses of HCV-796 are generally well tolerated with no serious treatment-emergent adverse events.

Based in Exton, Pa., ViroPharma is a biopharmaceutical company currently focusing its drug development activities in viral diseases including cytomegalovirus and hepatitis C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.